Skip to main content
Uncategorized

Genmedica Therapeutics announces the purchase by Ferrer of a minority stake in the company

By 9 de June de 2014November 18th, 2020No Comments
< Back to news
From left to right: Silvia García (PM), Ignacio Faus (CEO) and Olga Colomer (CFO) of Genmedica.
 09.06.2014

Genmedica Therapeutics announces the purchase by Ferrer of a minority stake in the company

Genmedica Therapeutics –a clinical stage biopharmaceutical company that develops new products for the treatment of type 2 diabetes, based in the PCB– announces the purchase of an 8% equity stake by Ferrer Internacional a leading diversified global pharmaceutical company. Genmedica Therapeutics has opened a €4M round of financing that is supported by its current shareholders and also by Asclepios BioResearch, the British venture capital firm that has been responsible in the past for funding the development of GMC-252. The new funds will be used to advance the clinical development of GMC-252 as well as for the preclinical development of additional compounds.


“We are delighted to welcome Ferrer as the latest shareholder in Genmedica Therapeutics. Ferrer will bring to the company invaluable expertise in the development and commercialization of new medicines for the benefit of the diabetic patient”, said Ignacio Faus, CEO of Genmedica Therapeutics.

“Ferrer International recognizes that the biotechnology sector is one of the leading providers of innovative and breakthrough medicines. We are looking forward to our participation in the development of Genmedica’s projects as a new shareholder”, said Antoni Villaró, COO of Ferrer.

GMC-252, the company’s most advanced compound, is a novel oral therapy for the treatment of type 2 diabetes. It works by targeting both inflammation and oxidative stress. GMC-252 has shown an excellent safety profile in a Phase I clinical trial that was recently completed in the United Kingdom. Genmedica is now preparing the next study, which will be a Phase II clinical trial to be conducted in diabetic patients.

Using its proprietary “OSIF” technology platform, the company is also developing additional novel compounds for the treatment of type 2 diabetes and other metabolic diseases, most notably obesity.

Genmedica Therapeutics is a clinical stage biopharmaceutical company that develops innovative, first-in-class products for the treatment of diabetes. The company is financed by a syndicate of local and international venture capital firms. Current major shareholders are ICF Capital, Uninvest, Caixa Capital Risc, Espai d´Inversions 2005, Innova 31 and Venture Cap. The clinical development of Genmedica’s most advanced molecule is financed by the British venture capital firm Asclepios BioResearch.

For further information [+]